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Background
• Abnormalities of  complement function plays an important role in a wide range 
of diseases including: rheumatoid arthritis, Crohn’s disease, ischaemia 
reperfusion injury, sepsis, myasthenia gravis, PNH, age related macular 
degeneration, thrombotic microangiopathies, SLE and the antiphospholipid 
syndrome.
• Eculizumab (Soliris) is FDA/NICE-approved for the treatment of aHUS and 
PNH. Cost: approximately $500,000 (€430,000) per patient per year.
• A standard dosing regime is used and complement activity is not monitored.
• A variety of pharmaceutical agents that inhibit complement are in 
development.
Complement inhibitors in development
Company Place Product Target Molecule Route Indication Phase
Amyndas USA Compstatin
Mini FH
C3
FH
Peptide
Peptide
Intraocular
Intraocular
AMD
AMD
Preclin
Preclin
Alnylam USA ALN225 C5 RNAi peptide s.c. PNH Preclin
Omeros USA OMS721 MASP2 Mini antibody s.c. aHUS, TTP PII
Akari
Therapeutics
UK Coversin C5 Protein s.c. aHUS, PNH PI
Adienne Italy Mubodina
Ergidina
C5
C5
Mini antibody
Mini antibody
s.c.
s.c.
aHUS, DDD
Transplant
Preclin
Preclin
Alexion USA ALX1103 C3 Protein s.c. PNH PI
Apellis USA APL-1 C3 Peptide Inhaled Asthma/COPD PI/II
InflaRx Ger. IFX-1
IFX-2
C5a Antibody
Antibody
i.v. Sepsis PI
Preclin
Alligator Swe. ADC1104 C5aR Antibody i.v. IRI Preclin
NovoNordisk Den. NN8209 C5aR Antibody i.v. Rh arthritis PI
Noxxon Ger. NOX-D20 C5a Spiegelmer ? i.v. or s.c. Sepsis Preclin
Ophthotech USA Zimura C5 Antibody Intraocular Wet AMD PII
CS-2100i method development
CS-2100i Method (research software)
Siemens Complement Reagents
Erythrocyte Reagent
• Sheep erythrocytes in stabiliser solution (NaCl, HEPES, Methylisothiazolinone)
Amboreceptor Reagent
• Rabbit antibodies to sheep erythrocytes, NaCl, CaCl2, MgCl2, HEPES, NaN3
Reagent Preparation
• Add 5 mL amboreceptor reagent to 1 vial of erythrocyte reagent and incubate at 37°C 
for 45 minutes
Analysis protocol 
•The analyser mixed 20 L serum with 200 L combined reagent (sensitized cells)
•The time taken to achieve 50% red cell lysis was measured, using absorbance at 660nm
•Assay standardised with pooled normal serum
Study design
A commercial CH50 ELISA (Quidel Corp) and an in-house lytic CH50 assay (using sheep 
erythrocytes (TCS Biosciences) and hemolysin (Sigma) were used as reference methods.
Although citrate plasma can be used in the automated assay, serum was preferred to avoid 
any irreversible effects of chelation on complement activity.
Calibration curve stability was measured over 5 days
The detection limit was determined by testing serial dilutions of normal serum.
Within day and between day imprecision was assessed by testing freshly thawed aliquots of 
serum 
Comparability was assessed in 75 sera from normal controls, patients with liver disease, 
thrombotic APS and non-APS thrombosis controls. 
Results
Detection limit 1.6%
Intra- & Inter-assay precision 2.5 & 7.0% (normal serum)
Reagents stable for >24hr on analyser (but need manual mixing 
prior to each run)
Serum prepared within 1 hr stable for 4hr at ambient temperature.
Serum prepared after 48 hours suffered a 10% loss of activity
Calibration curve stability 
Lysis time (s)
Concentration Day 1 Day 2 Day 3 Day 4 Day 5 %CV
6.25% 151.2 155.6 155.6 147.4 145.2 3.12
12.50% 77.1 78.4 77.8 76.8 74.8 1.78
25% 37.3 37.6 37.8 38 37.1 0.97
50% 23.4 23 23.6 23.7 23 1.41
100% 16.4 16.4 16.4 16.7 16.4 0.82
Comparability (75 Samples)
35 Normal subjects, 22 APS, 11 Thrombosis Controls, 7 Liver Disease
Conclusions
• The automated method showed good linearity, 
precision and comparability. 
• It allows the routine assessment of complement 
activity in a highly standardized manner. This may 
be particularly useful for monitoring the efficacy of 
new complement inhibitory drugs.
